Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market

Core Viewpoint - Brainstorm Cell Therapeutics has secured a strategic private placement of $1 million, reflecting confidence in its operational momentum and the value of its NurOwn® platform [1] Financing Details - The financing is structured in two tranches, with the first payment of $500,000 already received and the second payment of $500,000 expected within 30 days [1] - The common stock was priced at $0.60 per share, a significant premium to the $0.54 closing price on February 9, 2026 [1] - The investment includes 120% warrant coverage for five years with an exercise price of $1.00 per share, indicating a nearly 100% premium to the recent market close [1] Company Strategy and Future Plans - The financing follows a period of strategic activity, including finalizing the Phase 3b trial design under a Special Protocol Assessment (SPA) and discussions regarding a Citizens Petition for Accelerated Approval [1] - Proceeds from the financing will support ongoing regulatory initiatives, prepayments for the upcoming Phase 3b trial of NurOwn® in ALS, and general corporate purposes [1] About NurOwn® Technology - NurOwn® technology involves autologous MSC-NTF cells, which are designed to deliver neurotrophic factors and immunomodulatory cytokines to target neurodegenerative diseases [1] - The platform has received Orphan Drug designation from both the FDA and the EMA, with a Phase 3 trial in ALS completed and a second Phase 3b trial set to launch [1] Company Background - Brainstorm Cell Therapeutics is focused on developing autologous adult stem cell therapies for neurodegenerative diseases, with a proprietary platform aimed at modulating neuroinflammation and promoting neuroprotection [1]